Victory Capital Management
OCUL icon

Victory Capital Management’s Ocular Therapeutix OCUL Stock Holding History

Victory Capital Management’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$227K Buy
23,098
+570
+3% +$5.17K ﹤0.01% 2235
2026
Q1 		$191K Buy
22,528
+1,011
+5% +$9.64K ﹤0.01% 2202
2025
Q4 		$261K Buy
21,517
+4,733
+28% +$57.5K ﹤0.01% 2138
2025
Q3 		$196K Buy
16,784
+840
+5% +$10K ﹤0.01% 2227
2025
Q2 		$148K Sell
15,944
-206
-1% -$1.61K ﹤0.01% 2287
2025
Q1 		$118K Sell
16,150
-52,721
-77% -$405K ﹤0.01% 2294
2024
Q4 		$588K Buy
68,871
+51,671
+300% +$504K ﹤0.01% 1989
2024
Q3 		$150K Sell
17,200
-203
-1% -$1.67K ﹤0.01% 2272
2024
Q2 		$119K Buy
17,403
+4,695
+37% +$29K ﹤0.01% 2273
2024
Q1 		$116K Buy
12,708
+2,573
+25% +$18.3K ﹤0.01% 2286
2023
Q4 		$45.2K Buy
+10,135
New +$30K ﹤0.01% 2449
2022
Q3 		– Sell
-10,137
Closed -$41K – 2750
2022
Q2 		$41K Sell
10,137
-50
-0.5% -$189 ﹤0.01% 2571
2022
Q1 		$36K Sell
10,187
-289
-3% -$1.6K ﹤0.01% 2617
2021
Q4 		$73K Sell
10,476
-323
-3% -$2.51K ﹤0.01% 2618
2021
Q3 		$108K Sell
10,799
-381
-3% -$4.28K ﹤0.01% 2606
2021
Q2 		$159K Sell
11,180
-1,537,447
-99% -$23.4M ﹤0.01% 2555
2021
Q1 		$25.4M Buy
1,548,627
+461,855
+42% +$8.9M 0.03% 815
2020
Q4 		$22.5M Buy
+1,086,772
New +$16.1M 0.03% 836
2020
Q2 		– Sell
-7,329
Closed -$36K – 3018
2020
Q1 		$36K Buy
+7,329
New +$36.2K ﹤0.01% 2621
2019
Q4 		– Sell
-7,115
Closed -$22K – 3053
2019
Q3 		$22K Buy
+7,115
New +$31.8K ﹤0.01% 3014

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Victory Capital Management's OCUL Position: Q2 2026 in Review

Victory Capital Management increased its Ocular Therapeutix (OCUL) stake by 2.5% in Q2 2026, buying an estimated $5.17K and bringing the position to 23,098 shares worth $227K. The position accounts for ﹤0.01% of the portfolio, ranked #2235.

Victory Capital Management first reported a position in OCUL in Q3 2019 and has held it in 20 quarters since. The position peaked at $25.4M in Q1 2021. 263 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • Victory Capital Management held 23,098 shares of Ocular Therapeutix worth $227K as of Q2 2026.
  • Victory Capital Management bought 570 Ocular Therapeutix shares in Q2 2026, an estimated $5.17K.
  • Ocular Therapeutix made up ﹤0.01% of Victory Capital Management's portfolio in Q2 2026, its #2235 holding.
  • Victory Capital Management first reported a position in Ocular Therapeutix in Q3 2019 and has held it in 20 quarters since.
  • Victory Capital Management's Ocular Therapeutix position peaked at $25.4M in Q1 2021.
  • 263 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Victory Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.